Table 1.

The FDA Drug Label for Tafenoquine (Arakoda). Contraindicated in G6PD Deficiency. (2019)

PhenotypeWarnings and precautions
G6PD deficiencyHemolytic Anemia: G6PD testing must be performed before prescribing tafenoquine due to the risk of hemolytic anemia. Monitor individuals for signs or symptoms of hemolysis.
G6PD Deficiency in Pregnancy or Lactation: tafenoquine may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. Tafenoquine is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to tafenoquine through breast milk. Check infant’s G6PD status before breastfeeding begins.

G6PD: Glucose-6-phosphate dehydrogenase

This FDA table is adapted from (1).

From: Tafenoquine Therapy and G6PD Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.